Viking Therapeutics Plans to Release Financial Results
Viking Therapeutics, Inc. (NASDAQ: VKTX), a forward-thinking biopharmaceutical company, is gearing up to announce its financial results for the fourth quarter and the full year of 2025. The much-anticipated release will take place after market hours on Wednesday, February 11. This event signifies a crucial milestone for the company as it continues to advance its notable portfolio of medical therapies.
Conference Call Details
The company has scheduled a conference call to discuss these results and provide general updates on corporate affairs. Interested parties may join the call on February 11 at 4:30 p.m. Eastern Time. For those in the U.S., the call can be accessed by dialing (844) 850-0543, while international participants can call (412) 317-5199. Following the call, a telephone replay will be available until February 18 for attendees who wish to revisit the discussion.
Innovative Therapies in Development
Viking Therapeutics is dedicated to the development of novel therapies targeting metabolic and endocrine disorders. Their pipeline showcases some innovative treatments, including VK2735, a first-in-class dual agonist aimed at tackling various metabolic diseases. VK2735 is currently undergoing evaluation in two significant Phase 3 clinical trials—VANQUISH-1 and VANQUISH-2—with promising initial results demonstrating safety, tolerability, and beneficial clinical outcomes.
VK2809 for Lipid and Metabolic Disorders
In addition to VK2735, Viking is also making strides with VK2809, an oral medication designed to selectively target thyroid hormone receptors. This compound has shown remarkable potential, effectively meeting all primary and secondary endpoints in a Phase 2b study focused on non-alcoholic steatohepatitis (NASH) with fibrosis.
Advancing into Rare Diseases
The company is also venturing into the treatment of rare diseases with VK0214, a small molecule targeted for X-linked adrenoleukodystrophy (X-ALD). Early trials have demonstrated VK0214’s safety and ability to reduce problematic fatty acids significantly, marking a significant advancement in the treatment landscape for patients.
Looking Ahead
These developments showcase Viking Therapeutics' ambition to harness its expertise in metabolic research to deliver innovative treatments that could transform patient care. As Viking prepares to unveil its financial results, stakeholders are eager to see how the company’s promising pipeline reflects on its overall performance in this fast-evolving market.
Frequently Asked Questions
1. When will Viking Therapeutics announce its financial results?
Viking Therapeutics will announce its financial results on February 11, after market close.
2. How can I listen to the conference call?
To participate in the conference call, you can call (844) 850-0543 in the U.S. or (412) 317-5199 internationally.
3. What is VK2735?
VK2735 is a dual agonist being evaluated for the treatment of various metabolic disorders and is currently in Phase 3 clinical trials.
4. What is VK2809 used for?
VK2809 is an orally available selective thyroid hormone receptor beta agonist aimed at treating lipid and metabolic disorders, including NASH.
5. What are Viking's goals for 2025 and beyond?
Viking aims to advance its novel therapies through clinical trials and improve outcomes for patients with metabolic and endocrine disorders.
